Literature DB >> 9839551

Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms.

M Griffioen1, W T Steegenga, I J Ouwerkerk, L T Peltenburg, A G Jochemsen, P I Schrier.   

Abstract

Major Histocompatibility Complex (MHC, HLA in humans) class I antigens play an important role in cellular immunology by presenting antigens to T cells. Downregulation of MHC class I expression is thought to be a mechanism by which tumor cells escape from T cell-mediated lysis. In primary human melanomas and melanoma cell lines, HLA-B expression is frequently downmodulated, correlating with elevated expression of the c-myc oncogene. Transfection experiments have shown that c-myc induces HLA-B downregulation through a -68 to +13 base pairs (bp) core promoter fragment, containing CCAAT and TATA-like (TCTA) boxes. Since (i) c-myc has been reported to activate the human p53 promoter and (ii) p53 is capable of repressing a large array of basal promoters, we investigated whether c-myc-induced HLA-B abrogation is mediated by p53. In this article, it is shown that the HLA-B core promoter is indeed repressed by wild-type p53, making p53 a candidate for mediating c-myc-induced HLA-B downregulation. However, transfection of c-myc into p53-null cell lines still resulted in suppression of the basal HLA-B promoter, demonstrating that c-myc and p53 repress the minimal HLA-B promoter through independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839551     DOI: 10.1016/s0161-5890(98)00074-1

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

3.  Role of peroxisome proliferator-activated receptors alpha and gamma in gastric ulcer: An overview of experimental evidences.

Authors:  Lekha Saha
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 4.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

Review 5.  c-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases?

Authors:  Claudio Napoli; Lilach O Lerman; Filomena de Nigris; Vincenzo Sica
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

6.  Long-term expression changes of immune-related genes in prostate cancer after radiotherapy.

Authors:  Iris Eke; Molykutty J Aryankalayil; Michelle A Bylicky; Veit Sandfort; Claire Vanpouille-Box; Saravanan Nandagopal; Edward E Graves; Amato J Giaccia; C Norman Coleman
Journal:  Cancer Immunol Immunother       Date:  2021-08-25       Impact factor: 6.968

7.  The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer.

Authors:  Alessandra Fucci; Tommaso Colangelo; Carolina Votino; Massimo Pancione; Lina Sabatino; Vittorio Colantuoni
Journal:  PPAR Res       Date:  2012-09-06       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.